Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 11.41
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of MNMD is 27 and suggests 136% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
Buy
Sell